Allcyte was founded in 2016 by Nikolaus Krall, Gregory Vladimer, Berend Snijder and Giulio Superti-Furga as a spin-off of the CeMM Research Centre for Molecular Medicine of the Austrian academy of sciences.
Since then, Allcyte's mission has been to transform translational cancer research and how drugs are used in the clinic by providing unique, personalised insight into drug activity directly from live human tumour tissues.
Foundation: Allcyte is founded in 2016 by Nikolaus Krall, Berend Snijder, Giulio Superti-Furga and Gregory Vladimer as a spin-off of the CeMM Research Centre for Molecular Medicine of the Austrian academy of sciences.
EXALT I: With interim results published in 2017 in Lancet Hematology and the final results presented at ASH in late 2020, EXALT I is the world's first prospective interventional clinical study demonstrating that drug response measured in primary tumour tissues can prioritise clinically effective drugs. This makes Pharmacoscopy® the first-ever clinically validated functional precision medicine platform.
Seed Investment: Allcyte announces its USD 6 Mio Seed Round with a dedicated story in Fortune Magazine.